Herpes zoster vaccine composition
The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
1. A vaccine composition against chickenpox or herpes zoster comprising:
glycoprotein E of varicella-zoster virus;
a glucopyranosyl lipid adjuvant of the following Formula 1; and
a squalene:
wherein,
R 1 , R 3 , R 5 and R 6 are each independently C 10 -C 12 alkyl; and R 2 and R 4 are each independently C 8 -C 10 alkyl.
2. The vaccine composition of claim 1 , wherein the glucopyranosyl lipid adjuvant is the one of Formula 1 wherein R 1 , R 3 , R 5 and R 6 are C 11 alkyl.
3. The vaccine composition of claim 1 , wherein the glucopyranosyl lipid adjuvant is the one of Formula 1 wherein R 2 and R 4 are C 9 .
4. The vaccine composition of claim 1 , wherein the glucopyranosyl lipid adjuvant is contained in an amount of 7.5 μg to 20 μg in a single dose of the vaccine composition.
5. The vaccine composition of claim 4 , wherein the glucopyranosyl lipid adjuvant is contained in an amount of 9 μg to 18 μg in a single dose of the vaccine composition.
6. The vaccine composition of claim 1 , wherein the squalene is contained in an amount of 1% (v/v) to 7% (v/v) of the total vaccine composition.
7. The vaccine composition of claim 6 , wherein the squalene is contained in an amount of 1% (v/v) to 4% (v/v) of the total vaccine composition.
8. The vaccine composition of claim 1 , wherein the glycoprotein E is contained in an amount of 5μg to 100 μg in a single dose of the vaccine composition.